SCHEMBL1688339

SCHEMBL1688339

Cc1ccc(S(=O)(=O)Nc2ccccc2C(=O)O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 3/20 0.71
LMNA P02545 4/20 0.68
MCL1 Q07820 1/20 0.68
ALDH1A1 P00352 5/20 0.68
KDM4E B2RXH2 2/20 0.68
HSD17B10 Q99714 3/20 0.67
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
KCNA5 P22460 4/20 0.66
CYP2C9 P11712 3/20 0.66
CYP2C19 P33261 2/20 0.66
CYP1A2 P05177 2/20 0.66
HPGD P15428 2/20 0.66
POLB P06746 2/20 0.65
TSHR P16473 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
USP2 O75604 1/20 0.64
MAPT P10636 1/20 0.64
NOD2 Q9HC29 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14855770 0.92 KCNA5 (0.65) METAP2LMNAMCL1ALDH1A1KDM4E
SCHEMBL1466906 0.89 ALDH1A1 (0.72) METAP2LMNAMCL1ALDH1A1KDM4E
SCHEMBL27995 0.87 ALDH1A1 (0.74) METAP2LMNAALDH1A1HSD17B10KMT2A
Zinc Ion SCHEMBL9443911 0.86 LMNA (0.67) METAP2LMNAALDH1A1KDM4EHSD17B10
Lithium Ion SCHEMBL6112283 0.86 LMNA (0.67) METAP2LMNAALDH1A1KDM4EHSD17B10
SCHEMBL15821566 0.86 LMNA (0.67) METAP2LMNAALDH1A1KDM4EHSD17B10
SCHEMBL9402809 0.86 ACLY (0.73) METAP2LMNAMCL1ALDH1A1KDM4E
SCHEMBL2499921 0.86 LMNA (0.67) METAP2LMNAALDH1A1KDM4EHSD17B10
SCHEMBL16127963 0.86 ALDH1A1 (0.69) METAP2LMNAALDH1A1KDM4EHSD17B10
SCHEMBL3561943 0.85 LMNA (0.58) METAP2LMNAMCL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058977-A1 Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof INSTITUTE OF MATERIA MEDIC, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2004-03-25 US claimed
CN-1127482-C Sulfuryl diphenyl indole compound and preparation process and use in medicine INST OF MEDICINE CHINESE ACADE (CN) 2003-11-12 CN claimed
CN-1333206-A Sulfuryl diphenyl indole compound and preparation process and use in medicine INST OF MEDICINE CHINESE ACADE (CN) 2002-01-30 CN claimed
EP-0341536-B1 MIXTURES OF ALKENYLSUCCINIC ACIDS, ARYLSULFONYLANTHRANILIC ACIDS AND ALKANOL AMINES AND THEIR USE AS CORROSION INHIBITORS IN AQUEOUS SYSTEMS BASF Aktiengesellschaft (DE) 1992-01-02 EP claimed
EP-0341536-A1 Mixtures of alkenylsuccinic acids, arylsulfonylanthranilic acids and alkanol amines and their use as corrosion inhibitors in aqueous systems BASF Aktiengesellschaft (DE) 1989-11-15 EP claimed
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2024-08-20 US disclosed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 EP disclosed
EP-4140991-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2023-03-01 EP disclosed
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORPORATION 2022-11-17 US disclosed
EP-3802514-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2022-08-03 EP disclosed
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2022-07-19 US disclosed
EP-2968330-B1 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS SCRIPPS RESEARCH INST (US) 2021-09-29 EP disclosed
WO-2000078145-A1 MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-28 WO disclosed
US-6140513-A Color forming dye precursor, composition containing the same and color forming heat-sensitive recording material MITSUBISHI PAPER MILLS LIMITED (JP) 2000-10-31 US disclosed
EP-0308820-B1 ZINC, LEAD, AND/OR CALCIUMSALTS OF CARBOXYLIC ACIDS AND THEIR USE AS ANTICORROSIVE AGENTS BASF Lacke + Farben AG (DE) 1991-11-27 EP disclosed
US-4999134-A For alkyd resin coating systems, aqueous and nonaqueous BASF AKTIENGESELLSCHAFT (DE) 1991-03-12 US disclosed
EP-0308820-A1 Zinc, lead, and/or calciumsalts of carboxylic acids and their use as anticorrosive agents BASF Lacke + Farben AG (DE) 1989-03-29 EP disclosed
EP-0212010-A1 Color developers for pressure-sensitive or heat-sensitive recording papers THE STANDARD REGISTER COMPANY (US) 1987-03-04 EP disclosed
US-4623391-A COMPOUNDS HAVING ELECTRON-WITH DRAWING GROUPS WITHIN FIVE ATOMS OF A SULFANAMIDE THE STANDARD REGISTER COMPANY (US) 1986-11-18 US disclosed
US-4531139-A Color developers for pressure-sensitive or heat-sensitive recording papers THE STANDARD REGISTER COMPANY (US) 1985-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES LUC7L2, LYPLAL1, GUSB METAP2 820/4885LMNA 1478/4885MCL1 1048/4885
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB METAP2 820/4885LMNA 1478/4885MCL1 1048/4885
US-20040058977-A1 Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof PTGS2, PTGES2, PTGER2 METAP2 1188/4885LMNA 3726/4885MCL1 2311/4885
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB METAP2 820/4885LMNA 1478/4885MCL1 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.